Business ❯ Pharmaceutical Industry ❯ Market Dynamics

Sales Forecasting

Revenue Targets

FDA Reapproves GSK’s Blenrep for Multiple Myeloma in Narrow Combination Use

Regulators limited the relaunch to one regimen because safety concerns offset strong efficacy data.